Navigation Links
Array BioPharma To Present At The Wells Fargo Securities Research And Economics 2013 Healthcare Conference
Date:6/13/2013

BOULDER, Colo., June 13, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference in Boston.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Event:Wells Fargo Securities Research and Economics 2013 Healthcare ConferencePresenter:Ron Squarer, Chief Executive OfficerDate:Wednesday, June 19, 2013Time:9:15 a.m. Eastern Time Location:InterContinental Hotel,  Boston, MAWebcast:www.arraybiopharma.comAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma in 2013.  In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia HaugetoArray BioPharma Inc.303-386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
2. New Date And Time For Array BioPharma Presentation At The Jefferies 2013 Global Healthcare Conference
3. Array BioPharma Announces Proposed Public Offering of Convertible Debt
4. Two Array Invented MEK Inhibitors Showcased At ASCO
5. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
6. Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380
7. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
8. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
9. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
10. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
11. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Wells Specialty Pharmacy announces the acquisitions ... Rd in Winter Park, Florida and ... . Operations have been consolidated into the 3796 Howell Branch ... to announce that Chad Tomlinson , former Vice President ... effective immediately. Mr. Tomlinson is a Graduate of Florida State ...
(Date:1/20/2017)... LONDON , January 20, 2017 Avillion ... the appointment of Mark Weinberg , MD MBA as Chief ... , USA . ... Dr Weinberg has spent more than 17 ... "top 20" pharma companies to micro-cap biotech. Over the course of ...
(Date:1/19/2017)... 19, 2017 The global immunomodulators market ... 2025, according to a new study by Grand ... be predominantly driven by high R&D investments employed ... production of new and therapeutically advanced drugs. This ... at an unprecedented rate into the immunomodulators market ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has posted a new ... says this generation is a time like no other and society needs to understand the ... says he does not want to sound like an old bible beater because religion has ...
(Date:1/20/2017)... ... , ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality ... January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures ... its products to all clients at reasonable prices. At the ECRM trade show, it ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out of ... it attended the January ECRM trade show in Hilton Head, SC. , International ... determined to create a line of products that would elevate her fitness regime. At ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin ... alternative VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic ... during your workout. , After a successful launch in Sweden last year, the ...
(Date:1/20/2017)... ... ... account following a man who went on to support his country and serve the Lord. ... Haven, Florida and at the age of 5, his family moved to Pensacola Florida. In ... and got married right out of boot camp. , He and his wife raised ...
Breaking Medicine News(10 mins):